Tirzepatide not only aids in appetite suppression but also improves insulin sensitivity, particularly in a person's fat tissue.
Tirzepatide/Mounjaro injections. (Eli Lilly and Company)
The Central Drugs Standard Control Organisation’s (CDSCO) subject expert committee has approved pharmaceutical giant Eli Lilly’s Tirzepatide — an active ingredient in their blockbuster drugs Mounjaro and Zepbound – known for its weight loss benefits. However, the approval for it in India is specifically for diabetes treatment. India’s drug regulator CDSCO approved the import and marketing of Tirzepatide in the country.